Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis and John Hopkins Uni unite for allergy research

Sanofi-aventis has announced that it has teamed up with the Division of Allergy and Clinical Immunology at the John Hopkins University School of Medicine, Maryland under a three-year deal

Sanofi-aventis has announced that it has teamed up with the Division of Allergy and Clinical Immunology (ACI) at the John Hopkins University School of Medicine, Maryland under a three-year deal.

The partnership will undertake to develop new ways of treating respiratory diseases such as severe asthma and chronic obstructive pulmonary disease (COPD), along with immuno-allergic diseases.

For each research project, the two organisations will work on identifying new therapies, and will jointly design potential clinical studies and select biomarkers.

"This collaboration will allow sanofi-aventis and John Hopkins ACI to join their efforts to identify new therapeutic approaches, in particular in severe asthma and COPD," said Dr Marc Cluzel, senior vice president of research and development at sanofi-aventis.

Traditional treatment methods such as high dose inhaled steroids are not effective in all severe asthma sufferers. A better understanding of the effect the disease has on the functions of various cells in the body is needed in order to develop innovative therapies for these patients.

17th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics